Metformin and reduced risk of cancer in diabetic patients

Josie M. M. Evans; Louise A. Donnelly; Alistair M. Emslie-Smith; Dario R. Alessi; Andrew D. Morris

doi:10.1136/bmj.38415.708634.F7

Metformin and reduced risk of cancer in diabetic patients

Josie M. M. Evans, Louise A. Donnelly, Alistair M. Emslie-Smith, Dario R. Alessi, Andrew D. Morris

Research output: Contribution to journal › Article › peer-review

2050 Citations (Scopus)

Abstract

Metformin, widely given to patients with type 2 diabetes, works by targeting the enzyme AMPK (AMP activated protein kinase), which induces muscles to take up glucose from the blood. A recent breakthrough has found the upstream regulator of AMPK to be a protein kinase known as LKB1. LKB1 is a well recognised tumour suppressor. Activation of AMPK by metformin and exercise requires LKB1, and this would also explain why exercise is beneficial in the primary and secondary prevention of certain cancers. We hypothesise that metformin use in patients with type 2 diabetes may reduce their risk of cancer.

Original language	English
Pages (from-to)	1304-1305
Number of pages	2
Journal	BMJ
Volume	330
Issue number	7503
DOIs	https://doi.org/10.1136/bmj.38415.708634.F7
Publication status	Published - Jun 2005

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1136/bmj.38415.708634.F7

Cite this

@article{9639759b03614dc0abae798ca7794e05,

title = "Metformin and reduced risk of cancer in diabetic patients",

abstract = "Metformin, widely given to patients with type 2 diabetes, works by targeting the enzyme AMPK (AMP activated protein kinase), which induces muscles to take up glucose from the blood. A recent breakthrough has found the upstream regulator of AMPK to be a protein kinase known as LKB1. LKB1 is a well recognised tumour suppressor. Activation of AMPK by metformin and exercise requires LKB1, and this would also explain why exercise is beneficial in the primary and secondary prevention of certain cancers. We hypothesise that metformin use in patients with type 2 diabetes may reduce their risk of cancer.",

author = "Evans, {Josie M. M.} and Donnelly, {Louise A.} and Emslie-Smith, {Alistair M.} and Alessi, {Dario R.} and Morris, {Andrew D.}",

note = "dc.publisher: BMJ Publishing Group dc.description.sponsorship: East of Scotland Primary Care Research Network. ",

year = "2005",

month = jun,

doi = "10.1136/bmj.38415.708634.F7",

language = "English",

volume = "330",

pages = "1304--1305",

journal = "BMJ",

issn = "0959-8146",

publisher = "BMJ Publishing Group",

number = "7503",

}

TY - JOUR

T1 - Metformin and reduced risk of cancer in diabetic patients

AU - Evans, Josie M. M.

AU - Donnelly, Louise A.

AU - Emslie-Smith, Alistair M.

AU - Alessi, Dario R.

AU - Morris, Andrew D.

N1 - dc.publisher: BMJ Publishing Group dc.description.sponsorship: East of Scotland Primary Care Research Network.

PY - 2005/6

Y1 - 2005/6

N2 - Metformin, widely given to patients with type 2 diabetes, works by targeting the enzyme AMPK (AMP activated protein kinase), which induces muscles to take up glucose from the blood. A recent breakthrough has found the upstream regulator of AMPK to be a protein kinase known as LKB1. LKB1 is a well recognised tumour suppressor. Activation of AMPK by metformin and exercise requires LKB1, and this would also explain why exercise is beneficial in the primary and secondary prevention of certain cancers. We hypothesise that metformin use in patients with type 2 diabetes may reduce their risk of cancer.

AB - Metformin, widely given to patients with type 2 diabetes, works by targeting the enzyme AMPK (AMP activated protein kinase), which induces muscles to take up glucose from the blood. A recent breakthrough has found the upstream regulator of AMPK to be a protein kinase known as LKB1. LKB1 is a well recognised tumour suppressor. Activation of AMPK by metformin and exercise requires LKB1, and this would also explain why exercise is beneficial in the primary and secondary prevention of certain cancers. We hypothesise that metformin use in patients with type 2 diabetes may reduce their risk of cancer.

U2 - 10.1136/bmj.38415.708634.F7

DO - 10.1136/bmj.38415.708634.F7

M3 - Article

SN - 0959-8146

VL - 330

SP - 1304

EP - 1305

JO - BMJ

JF - BMJ

IS - 7503

ER -

Metformin and reduced risk of cancer in diabetic patients

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this